# Clinical Trial of Keluoxin Capsules in the Treatment of Diabetic Kidney Disease with Diabetic Retinopathy

Study · id `cardio:ct-nct06660940` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06660940](<https://clinicaltrials.gov/study/NCT06660940>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06660940

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 460 participants.

## Technical summary

Registry record NCT06660940. Randomized; quadruple masking; primary purpose treatment. Start 2024-10 (anticipated); primary completion 2027-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 460 participants (planned count; ClinicalTrials.gov record NCT06660940, source copy `cardio:ctgov-nct06660940-2024-10-28`, retrieved 2026-10-26)
- Planned start: 2024-10 (anticipated) (ClinicalTrials.gov record NCT06660940, source copy `cardio:ctgov-nct06660940-2024-10-28`, retrieved 2026-10-26)
- Primary completion: 2027-10 (anticipated) (ClinicalTrials.gov record NCT06660940, source copy `cardio:ctgov-nct06660940-2024-10-28`, retrieved 2026-10-26)
- Completion: 2027-10 (anticipated) (ClinicalTrials.gov record NCT06660940, source copy `cardio:ctgov-nct06660940-2024-10-28`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06660940-2024-10-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: Clinical Trial of Keluoxin Capsules in the Treatment of Diabetic Kidney Disease with Diabetic Retinopathy
- Condition: Diabetic Kidney Disease
- Condition: Diabetic Retinopathy
- Intervention (Drug): Keluoxin Capsules
- Intervention (Drug): Keluoxin Capsule Simulants
- Intervention (Drug): Irbesartan
- Lead sponsor: Chinese PLA General Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Diabetic kidney disease (`cardio:diabetic-nephropathy`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Chinese PLA General Hospital (`cardio:org-chinese-pla-general-hospital`)

## Provenance

Content hash: 0f105bc403a0df5c371ce6e049e2accf95bea15c8f70d750da1dae4dd813bd05
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
